Table 3 Outcomes pooled across the entire study area, over time
Outcomes | Baseline year mean value observed (95%CI) | Trial year 1 mean value observed (95%CI) | Trial year 2 mean value observed (95%CI) |
|---|---|---|---|
EIR (indoors + outdoors)a | 0.010 (0.006, 0.015) | 0.011 (0.007, 0.016) | 0.001 (0.000, 0.003) |
All Anopheles females indoorsa | 0.119 (0.099, 0.140) | 0.095 (0.077, 0.112) | 0.023 (0.015, 0.032) |
A. arabiensis females indoorsa | 0.101 (0.082, 0.120) | 0.049 (0.036, 0.061) | 0.005 (0.001, 0.009) |
A. funestus females indoorsa | 0.010 (0.004, 0.016) | 0.040 (0.029, 0.052) | 0.013 (0.006, 0.020) |
All Anopheles females outdoorsa | 0.178 (0.153, 0.203) | 0.116 (0.096, 0.135) | 0.047 (0.034, 0.060) |
A. arabiensis females outdoorsa | 0.158 (0.134, 0.181) | 0.068 (0.053, 0.083) | 0.009 (0.003, 0.014) |
A. funestus females outdoorsa | 0.006 (0.002, 0.011) | 0.041 (0.030, 0.053) | 0.035 (0.024, 0.046) |
Prevalence positive malaria RDT (%), women 15–49 years | 19.2 (17.0, 21.6) | 8.6 (7.1, 10.4) | 15.1 (13.0, 17.4) |
Prevalence positive malaria RDT (%), children 6–59 months | 33.8 (30.8, 36.9) | 19.3 (16.8, 22.1) | 22.4 (19.4, 25.8) |
Prevalence positive malaria RDT (%), children 6–23 months | 28.7 (23.8, 34.0) | 13.3 (9.8, 17.8) | 14.7 (10.7, 19.8) |
Prevalence positive malaria RDT + fever/tempb (%), women 15–49 years | 5.2 (4.0, 6.6) | 1.3 (0.8, 2.1) | 2.5 (1.7, 3.6) |
Prevalence positive malaria RDT + fever/tempb (%), children 6–59 months | 14.2 (12.1, 16.6) | 5.8 (4.4, 7.5) | 5.2 (3.7, 7.2) |
Prevalence positive malaria RDT + fever/tempb (%), children 6–23 months | 12.3 (9.1, 16.5) | 3.0 (1.5, 5.7) | 1.3 (0.4, 3.7) |
Hb, g/dL, women 15–49 years | 11.87 (11.78, 11.97) | 12.23 (12.15, 12.31) | 12.62 (12.54, 12.71) |
Hb, g/dL, children 6–59 months | 10.52 (10.41, 10.62) | 10.86 (10.76, 10.96) | 11.14 (11.03, 11.25) |
Hb, g/dL, children 6–23 months | 10.17 (10.00, 10.35) | 10.34 (10.17, 10.52) | 10.81 (10.64, 10.98) |